ArticleBJC reports2026
Contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM pathogenic variant carriers in two large cohort studies.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAll breast cancer (BC) patients have a risk of developing contralateral BC (CBC). This will be higher in women carrying a BC susceptibility gene pathogenic variant (PV), but specific risk estimates are lacking. We addressed this in a study-level meta-analysis of two large, recent cohort studies that used Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) project and Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium data.
methodsWe used population risks from the Netherlands to estimate 10-year cumulative CBC risks for BRCA1, BRCA2, PALB2, CHEK2, and ATM PV carriers. We estimated pooled hazard ratios (HRs) in meta-analyses using the generic inverse-variance method and assuming random effects. We stratified by first BC estrogen receptor (ER) status.
resultsAmong 462 BRCA1, 590 BRCA2, 796 CHEK2, 297 PALB2, and 345 ATM PV carriers, we estimated 10-year cumulative CBC risks of 10.1% (95% confidence interval (CI):7.5-13.6%) for BRCA1, 10.2% (95%CI:7.4-13.9%) for BRCA2, 7.1% (95%CI:3.4-14.3%) for PALB2, 8.0% (95%CI:5.7-11.1%) for CHEK2 (any PV), 8.5% (95%CI:5.9-12.3%) for CHEK2 del.1100 C, and 4.5% (95%CI:2.5-8.0%) for ATM PV carriers. We found elevated HRs in BRCA1 (HR:2.8, 95%CI:2.1-3.6), BRCA2 (HR:2.8, 95%CI:2.1-3.7), and CHEK2 PV carriers (all PVs: HR:2.1, 95%CI:1.6-2.9. del.1100 C PVs only: HR:2.3, 95%CI:1.6-3.3). We found no significantly elevated risks in PALB2 (HR:1.9, 95%CI:0.9-3.8) or ATM (HR:1.2, 95%CI:0.7-2.1) PV carriers. We saw increased risks in BRCA1/2 and CHEK2 PV carriers following ER-positive BC, and in BRCA1/2 and PALB2 PV carriers following ER- negative BC.
conclusionBC survivors carrying BRCA1, BRCA2, and CHEK2 PVs and ER-negative BC survivors carrying PALB2 PVs are at two-fold or higher CBC risks. These estimates may assist clinical decision making for management of the contralateral breast.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.